Current status and prospects of hematopoietic stem cell transplantation in China

Wang, Xiaoqi; Huang, Ruihao; Zhang, Xiaohui; Zhang, Xi

doi:10.1097/cm9.0000000000002235

Cited by 18 publications

(8 citation statements)

References 97 publications

(179 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for HMs [ 4 ]. Nonetheless, challenges like poor graft function, graft-versus-host disease (GVHD), and disease recurrence after transplantation persist [ 5 ]. Over the past decade, new immunotherapeutic approaches have emerged for the treatment of HMs, including immune checkpoint inhibitors (ICIs), cytokines, therapeutic antibodies, cancer vaccines, adoptive cell therapy(ACT), and immune system modulators.…”

Section: Introductionmentioning

confidence: 99%

Advances in nano-immunotherapy for hematological malignancies

Xu,

Liu,

Fan

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as a validated and crucial treatment modality for patients with HMs. Despite notable advancements having been made in understanding and implementing immunotherapy for HMs over the past decade, several challenges persist. These challenges include immune-related adverse effects, the precise biodistribution and elimination of therapeutic antigens in vivo, immune tolerance of tumors, and immune evasion by tumor cells within the tumor microenvironment (TME). Nanotechnology, with its capacity to manipulate material properties at the nanometer scale, has the potential to tackle these obstacles and revolutionize treatment outcomes by improving various aspects such as drug targeting and stability. The convergence of nanotechnology and immunotherapy has given rise to nano-immunotherapy, a specialized branch of anti-tumor therapy. Nanotechnology has found applications in chimeric antigen receptor T cell (CAR-T) therapy, cancer vaccines, immune checkpoint inhibitors, and other immunotherapeutic strategies for HMs. In this review, we delineate recent developments and discuss current challenges in the field of nano-immunotherapy for HMs, offering novel insights into the potential of nanotechnology-based therapeutic approaches for these diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Advances in nano-immunotherapy for hematological malignancies

Xu,

Liu,

Fan

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…In China, the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) reported 18,110 HSCTs in a single year (2021), contributing to a total of 90,436 HSCTs since 2008. To date, 174 medical centers have been registered as having a certi cate to perform HSCT [7].…”

Section: Introductionmentioning

confidence: 99%

Hospital-Based Surveillance System Development in Patients with Hematological Malignancies undergoing Bone Marrow Transplant in Middle-Income Countries- the Case of Iran experience: Research Protocol

Oshnouei,

Jebraeily,

Asadi-Lari

et al. 2024

Preprint

View full text Add to dashboard Cite

Background In patients with hematological malignancies undergoing bone marrow transplants, both cancer surveillance programs and cancer registries play crucial roles in monitoring and improving patient outcomes. This research protocol aims to establish a hospital-based surveillance system for patients with hematological malignancies undergoing bone marrow transplantation (BMT) in Iran, utilizing a mixed-methods approach. Methods The study will involve quantitative data collection through medical record reviews and qualitative data collection through action research. To evaluate the feasibility and acceptability of the surveillance system among healthcare providers and patients, an assessment was conducted. This involved organizing an expert panel and conducting focus groups. Given the absence of a standardized data collection format for the patients under study, we are taking steps to develop a Bone Marrow Transplantation Registry Electronic System in educational hospitals. Results We utilized a standardized format developed by the EBMT and CIBMTR, along with input from expert panels and focus groups, to review the literature on hematological malignancies. We have created a Bone Marrow Transplant Registry Checklist, designed as a tool for data collection. It incorporates validated MDS elements tailored to five distinct types of hematological malignancies. We utilized a passive data collection method to continuously gather pertinent information and created a web-based data collection tool for continuous monitoring and evaluation of treatments. Analytical reports were generated in the form of operational dashboards, providing valuable feedback on analyses during the surveillance process. A pilot test of the registry surveillance system was conducted to ensure alignment with standard procedures and to identify and address any systematic or random errors. Conclusions This research protocol outlines the methodology for establishing a system and emphasizes the importance of implementing standardized monitoring protocols in middle-income countries to enhance the evaluation of treatment outcomes among patients with hematological malignancies undergoing HSCT. This system can help identify gaps in available data and treatment modalities during procedures like HSCT. It can facilitate quality improvement and ultimately enhance patient outcomes by engaging with other decision-makers and supporting the growing efforts in middle-income countries in the concept of action research.

show abstract

“…No entanto, antes de serem utilizadas em terapias clínicas, as CTH precisam ser caracterizadas e diferenciadas das células não-tronco presentes no CCU. A diferenciação das CTH pode ser realizada por meio de análises morfológicas, imunofenotípicas e moleculares, que permitem identificar as células progenitoras hematopoiéticas e sua capacidade de diferenciação 4 .…”

Section: Introductionunclassified

Terapia Com Células Tronco Hematopoiéticas Colhidas Do Cordão Umbilical Em Doenças Neurológicas

Silva,

Gomes,

Santos

et al. 2024

Rev. Contemp.

View full text Add to dashboard Cite

INTRODUÇÃO: As doenças neurológicas representam um grande desafio para a medicina, pois muitas delas ainda não têm cura e a sua progressão pode levar à incapacidade funcional e à perda da qualidade de vida do paciente. Dentre as diversas estratégias terapêuticas estudadas para o tratamento de doenças neurológicas, a terapia com células-tronco vem ganhando destaque. Apesar do crescente interesse na terapia com células-tronco para doenças neurológicas, ainda há uma escassez de trabalhos que explorem especificamente o potencial terapêutico das células-tronco hematopoiéticas (CTH) do cordão umbilical nesse contexto. OBJETIVO: avaliar a eficácia e a segurança da terapia com células-tronco hematopoiéticas colhidas do cordão umbilical em doenças neurológicas, incluindo doenças cerebrais, medulares e ganglionares. METODOLOGIA: foi realizado um extenso levantamento bibliográfico e a revisão integrativa buscou examinar as opções terapêuticas disponíveis, bem como analisar a efetividade dessas abordagens no que se refere à melhoria dos sintomas neurológicos, regeneração do tecido afetado, controle da progressão da doença e prevenção de complicações adicionais. Os trabalhos selecionados foram publicados no período de 2018 a 2023 a partir de pesquisa realizada nas bases de dados Medline, Pubmed, Portal Regional da BVS e Lilacs. RESULTADOS: Embora o tratamento de condições neurológicas com células-tronco hematopoiéticas do cordão umbilical ainda seja experimental, resultados positivos têm sido relatados em crianças com paralisia cerebral e encefalopatia hipóxica isquêmica, incluindo melhora da função cognitiva e motora. CONSIDERAÇÕES FINAIS: Apesar dos avanços alcançados até o momento, ainda há muito a ser descoberto sobre o uso terapêutico das CTH. É necessário compreender melhor os mecanismos de diferenciação e a interação das CTH com o ambiente microcelular para otimizar as estratégias de transplante e melhorar os resultados clínicos. Além disso, a identificação de marcadores específicos que permitam a seleção e a expansão das CTH de forma mais eficiente é um campo de pesquisa em constante evolução.

show abstract

Current status and prospects of hematopoietic stem cell transplantation in China

Cited by 18 publications

References 97 publications

Advances in nano-immunotherapy for hematological malignancies

Advances in nano-immunotherapy for hematological malignancies

Hospital-Based Surveillance System Development in Patients with Hematological Malignancies undergoing Bone Marrow Transplant in Middle-Income Countries- the Case of Iran experience: Research Protocol

Terapia Com Células Tronco Hematopoiéticas Colhidas Do Cordão Umbilical Em Doenças Neurológicas

Contact Info

Product

Resources

About